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Summary
“Humanised” mouse models have emerged over past
years as powerful tools for investigating human
haematopoiesis and immunity. They allowed the identifi-
cation of key factors for the maintenance and function of
normal and leukaemic human haematopoietic stem cells.
These findings have been widely used to dissect the
pathogenesis of multiple myeloid and lymphoid neo-
plasms, such as acute myeloid leukaemia and acute lym-
phoblastic leukaemia. Furthermore, these models can
serve as a stepping-stone to clinical trials by testing novel
drugs that target leukaemic stem cells. The investigation
of human immunity in vivo is also of great interest in both
the context of understanding the innate and adaptive im-
mune system and responses to viral infections with ex-
clusive human tropism, such as Epstein-Barr virus and
human immunodeficiency virus. This review focuses on
recent advances in the study of human haematopoiesis
and immunity in humanised mouse models, underlining
their relevance and limitations.
Key words: humanised mouse models, xenograft,
leukaemia, HIV, EBV, PDX
Introduction
The need to understand normal or malignant human cell
development and disease heterogeneity, and to investigate
novel therapeutic strategies in order to accelerate their
transition into clinical trials, strongly supported the devel-
opment of “humanised” mouse models [1, 2]. Another im-
portant driving force for the development of these models
is the ethical concerns raised by clinical trials in humans.
Three major advancements over past decades have sig-
nificantly shaped the field (fig. 1). The first was the dis-
covery of a spontaneous autosomal recessive mutation in
the Prkdc gene, termed Prkdcscid (Prkdc: protein kinase,
DNA activated, catalytic polypeptide; scid: severe com-
bined immunodeficiency) in C.B-17 mice (called SCID
mice). This permitted low engraftment of human fetal tis-
sues, peripheral blood mononuclear cells and haematopoi-
etic stem cells (HSCs) owing to a T and B cell deficiency
[3–5]. Low human haematopoietic engraftment in C.B-17
mice is due to a tendency to develop functional mouse T
and B cell immunity (termed “leakiness”) and normal nat-
ural killer (NK) cell activity [6]. Furthermore, mutations
in the locus of one of the recombination-activating genes
(RAG1 or RAG2) resulted in Rag1tm1Mom or Rag2tm1.1Cgn
mice with a T- and B-cell deficiency similar to that seen in
C.B-17 mice, but in addition rendered them resistant to ra-
diation and leakiness [7].
The second advancement was the development of
NOD.CB17-Prkdcscid/J mice, generated by backcrossing
mice with the Prkdcscid mutation to mice on the NOD
(non-obese diabetic) background [8]. In comparison to the
C.B-17 mice, these mice showed improved engraftment of
HSCs as a result of lower NK cell activity and defects in
their innate immunity, although they had short life-spans
due to spontaneous development of thymic lymphomas
[8].
The introduction of a targeted mutation in the locus of
the interleukin-2 receptor (IL-2R) γ-chain, which leads to
NK cell depletion, was the third key achievement that led
to a substantially higher engraftment of functional human
HSCs [9–12]. Today, the NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ
(NSG) model that resulted represents the most commonly
used host strain for xenograft experiments. Although the
introduction of NSG mice has significantly advanced the
field, NSG mice fail to support maturation of human B
cells into memory and plasma cells. In addition, T cell de-
velopment lacks thymic support and the development of
innate immunity (i.e., NK cell and macrophage develop-
ment) is limited [13].
A crucial immune determinant of human haematopoietic
cell survival identified in xenograft models is macrophage
tolerance [14, 15]. Binding of human CD47 on human
haematopoietic cells to mouse signal regulatory protein-
alpha (SIRPα) on resident host macrophages generates a
“don’t eat me” signal that leads to inhibition of phagocyto-
sis, protects the transplanted human cells and consecutive-
ly contributes to the human cell survival in vivo [15, 16].
The interaction between human CD47 and mouse SIRPα
is present in mice on a NOD background since the mouse
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SIRPα IgV domain is very similar to the human homo-
logue.
In addition, the recognition of the importance of cytokines
and growth factors secreted by bone marrow stromal cells
in supporting HSC development led to the development
of “next-generation” humanised mouse strains, such as
MISTRG mice [17]. These mice were genetically engi-
neered to express human macrophage colony stimulating
factor (M-CSF), interleukin-3 (IL-3), SIRPα, thrombopoi-
etin and granulocyte-macrophage-CSF (GM-CSF) (abbre-
viated MISTRG) to allow efficient human haematopoietic
development. In contrast to previous models, these support
the development of functional human macrophages and
NK cells [17]. Moreover, these mice favour myelomono-
cytic differentiation and the engraftment of mobilised pe-
ripheral blood mononuclear cells, which is limited in the
NOD.CB17-Prkdcscid/J and NSG mouse models [18]. Re-
cently, an improved “next-generation” humanised mouse
strain of MISTRG that harbours an additional knock-in
of human interleukin-6 (IL-6) was developed. These mice
support efficient engraftment of human plasma cell neo-
plasms, which particularly rely on the presence of IL-6 [19,
20]. Improved models that support multilineage engraft-
ment of human HSCs while minimising the mouse HSC
compartment by ablating mouse cells were also developed.
These models were generated by the introduction of mu-
tations in the Kit receptor, which is vital for HSC mainte-
nance and function, in immunodeficient mouse strains on
the BALB/c (BRg KitWv/Wv) or NOD (NSG KitWv/Wv) back-
ground [21].
Although the humanised mice field has advanced exten-
sively, there are still obstacles that need to be overcome in
order to generate a model that fully recapitulates the com-
plexity of the human haematopoietic system. This review
focuses on current advances in the development of human-
ised mouse models for human haematopoiesis and immu-
nity, highlighting their relevance and limitations.
Haematopoiesis
Normal human haematopoiesis
The haematopoietic system is a hierarchically organised
cellular system, in which HSCs reside at the apex and are
characterised by their ability to self-renew and to differen-
tiate into mature blood cells of the myeloid and the lym-
phoid lineage (fig. 2 and table 1). By definition, human
HSCs are capable of repopulating immune-compromised
mice and are enriched in the lineage-marker negative
(Lin−), CD34+, CD38−, CD90+ (Thy1+) and CD45RA−
population in the human fetal liver / fetal bone marrow,
umbilical cord blood and adult bone marrow [24–30]. Lat-
er, CD49f integrin was identified as a marker that further
enriches for human HSCs in umbilical cord blood samples.
In combination with the high efflux of the mitochondrial
dye rhodamin 123, 14 to 28% (i.e., 1 in 3.5–7 cells) of
functional umbilical cord blood human HSCs that express
the surface phenotype mentioned above are capable of en-
grafting NSG mice at the single cell level [22]. HSCs give
rise to multipotent progenitors (MPPs), which in turn give
rise to oligopotent multilymphoid progenitors (MLPs) and
common myeloid progenitors (CMPs), which further dif-
ferentiate into unipotent progenitors (fig. 2). For exam-
ple, CMPs give rise to lineage-committed megakaryocyte/
erythrocyte progenitors (MEPs) and granulocyte/monocyte
progenitors (GMPs). MPPs are distinguished from HSCs
by the lack of CD49f expression (table 1) [22]. Recently,
the surface marker profile of CMPs, MEPs and MPPs was
re-defined by the addition of CD71 and the thrombopoi-
Figure 1: Historical development of humanised mouse strains. The first major advancement was the discovery of a mutation in the Prkdc
gene that led to development of SCID mice. The second was the development of NOD.CB17-Prkdcscid/J (NOD scid) mice, generated by back-
crossing mice with the Prkdcscid mutation to mice on the NOD (non-obese diabetic) background. The introduction of a targeted mutation in the
locus of the interleukin-2 receptor (IL-2R) γ-chain led to the development of the NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice, which represents
the most widely used host strain so far. Further discoveries, took into account the importance of cytokines and growth factors in supporting
HSC development, which led to the development of “next-generation” humanised mouse strains, such as MISTRG mice.
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etin receptor, which allowed better purification from the
rest of the populations in the haematopoietic tree [31].
Furthermore, it was shown that cells with megakaryocyte/
erythroid potential branch out directly from HSCs, rather
than from MEPs, a concept that resembles the mouse
haematopoietic tree [32].
The regulation of HSC self-renewal and differentiation by
cell-intrinsic and cell-extrinsic factors has been extensive-
ly investigated in the mouse system using knockout mod-
els, whereas their human analogues have not been explored
because of the lack of suitable humanised model. Nonethe-
less, some key human HSCs factors have been cross-con-
firmed and/or newly identified. HSCs are a quiescent cell
population that mostly reside in the G0 phase of the cell cy-
cle [33]. Recently, it was demonstrated that cyclin-depen-
dent kinase C (CDK6) levels regulate the kinetics of quies-
cence exit of human HSC subsets in xenograft models [34].
Further intrinsic factors that have been associated with the
human HSC state include the transcription factors SOX8,
SOX18, HoxB4, HES1 and BMI1. However, their function-
al role remains to be validated in xenograft studies. Ex-
trinsic factors that support human HSC function and en-
graftment in xenograft models include the macrophage re-
ceptor SIRPα (see introduction) and thrombopoietin. Both
human factors have been genetically introduced into im-
mune-compromised mice in order to facilitate normal and
malignant human HSC engraftment [35, 36]. Overall, there
are still many gaps in the current knowledge of normal hu-
man HSC maintenance and function, which with the de-
velopment of new humanized mouse models can be further
elucidated.
Malignant human haematopoiesis
Myeloid neoplasms
Patient-derived xenograft (PDX) models have been exten-
sively used to dissect the pathogenesis of acute myeloid
leukaemia (AML) at the clonal level and for preclinical
testing of novel therapeutic regimens. One major contri-
bution of PDX models to the AML field is the identi-
Figure 2: Hierarchy within human haematopoietic system. The tree-like organisation of the haematopoietic system is composed of
haematopoietic stem cells (HSCs) with long-term self-renewal capacity that reside at the apex of the hierarchy and through multipotent and lin-
eage-committed progenitors generate the differentiated mature cells with no or limited self-renewal capacity.B/NK = B and NK cell progenitor;
cDC = conventional dendritic cells; CDP = common dendritic cell progenitor; CMP = common myeloid progenitor; Erb = erythroblast; GMP =
granulocyte monocyte progenitor; HSC = haematopoietic stem cells; MDP = monocyte and dendritic cell progenitor; MEP = megakaryocyte-
erythrocyte progenitor; Mk = megakaryocytes; Mk/ErP = megakaryocyte/erythrocyte progenitor; MLP = multi-lymphoid progenitor; MPP = mul-
ti-potent progenitor; pDC = plasmocytoid dendritic cells; PreGr = pre granulocytes; TP = T cell progenitor
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fication of preleukaemic (pre-LSCs) and leukaemic stem
cells (LSCs) (fig. 3). By definition, LSCs can repopulate
immune-compromised mice and propagate disease when
transplanted from the primary into secondary recipients. It
is well accepted that LSCs initiate disease and their per-
sistence after therapy causes relapse in patients [38, 39].
Thus, the identification and therapeutic targeting of LSCs
is of high clinical relevance.
More recently, AML PDX models led to the identification
of pre-LSCs. Pre-LSCs are HSCs that harbour recurrent
somatic mutations and, with the acquisition of additional
genetic hits, can lead to AML initiation and relapse [37,
40]. Mutations present in pre-LSCs are mostly found in
genes involved in chromatin remodelling, whereas muta-
tions that confer growth advantage to the AML clone oc-
cur later in AML development [41]. In contrast to LSCs,
Table 1: Human haematopoietic stem and progenitor cell phenotypes.
Haematopoietic cell population Cell surface marker combination
HSPC Lin−CD34+CD38−
HSC Lin−CD34+CD38−CD45RA-CD90+Rho−/lowCD49f+
MPP Lin−CD34+CD38−CD45RA−CD90−CD49f−
*MPP F1 Lin−CD34+CD38−CD45RA−CD90−CD49f−CD71−BAH1−
*MPP F2/3 Lin−CD34+CD38−CD45RA−CD90−CD49f−CD71+BAH1−/+
MLP Lin−CD34+CD38−CD45RA+CD90−/low
CMP CD34+CD38+CD45RA−CD10−Flt3+
*CMP F1 CD34+CD38+CD45RA−CD10−Flt3+CD71−BAH1−
*CMP F2/3 CD34+CD38+CD45RA−CD10−Flt3+CD71+BAH1−/+
MEP CD34+CD38+CD45RA−CD10−Flt3-
*MEP F1 CD34+CD38+CD45RA−CD10−Flt3−CD71−BAH1−
*MEP F2/3 CD34+CD38+CD45RA−CD10−Flt3−CD71+BAH1−/+
GMP CD34+CD38+CD45RA+CD10−Flt3+
B/NK CD34+CD38+CD45RA+CD10+
B/NK = B and NK cell progenitor; CMP = common myeloid progenitor; GMP = granulocyte monocyte progenitor; HSC = hematopoietic stem cells; HSPC = hematopoietic
stem and progenitor cells; MEP = megakaryocyte-erythrocyte progenitor; MPP = multi-potent progenitor; MLP = multi-lymphoid progenitor; CMPs are found in cells that
are CD34+CD38+CD10−Flt3+CD45RA−, MLPs are CD34+CD38−Thy1−CD45RA+, whereas MEPs and GMPs are CD34+CD38+CD10−Flt3−CD45RA− and
CD34+CD38+CD10−Flt3+CD45RA+ respectively [22, 23].
Figure 3: Concept of acute myeloid leukaemia (AML) xenograft models as an example for myeloid neoplasms. PDX models reflect
phenotypic as well as genetic features of myeloid neoplasms. In AML, the HSC compartment consists of preleukaemic stem cells (pre-LSCs)
and leukaemic stem cells (LSCs) that harbour somatic mutations. Transplantation of AML cells from the initial diagnosis into PDX models
leads to AML development in vivo. Genetically aberrant pre-LSCs can persist in patient remission, but lead to multilineage (normal) repopula-
tion in PDX models. Frequently, the persistence of pre-LSCs that acquire additional somatic mutations is at the origin of disease relapse,
which can be reproduced in PDX models (adapted from [37]).
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pre-LSCs lead to multilineage repopulation in PDX mod-
els, which makes it an excellent model to study the pro-
gression of preleukaemic lesions to overt AML.
Although PDX models significantly contributed to the
AML field by enabling LSCs to be identified and charac-
terised, the knowledge extracted from these models also
answered more clinically related questions. In particular,
potentially critical therapeutic factors for the survival of
LSCs have been identified [42]. Among these, the im-
munoglobulin superfamily member CD47, which is highly
expressed on LSCs, has been shown to protect LSCs from
innate immune surveillance [43, 44]. Targeting CD47 in
the AML PDX models demonstrated significant efficacy
and constituted the basis for currently on-going clinical tri-
als in AML, other haematopoietic neoplasms and solid tu-
mours [45]. Furthermore, the gene expression profile of
AML stem and progenitor fractions was correlated with
AML development in the PDX model and led to the iden-
tification of an AML gene expression signature that corre-
lates with clinical outcome and may be used for risk strati-
fication in future clinical trials [46].
The relevance of AML PDX models has been questioned
in the past since immune-compromised hosts such as
NOD.CB17-Prkdcscid/J and NSG mice support engraft-
ment of only a fraction of all AML patient samples. In par-
ticular, AML with a favourable risk profile was shown to
poorly engraft conventional models. In an attempt to ex-
tend the spectrum of transplantable AML, a defined sub-
group of AML characterised by the presence of an inver-
sion of chromosome 16, excellent response to conventional
chemotherapy, but poor engraftment in NSG mice, was
investigated in MISTRG mice (see introduction) [47]. In
contrast to NSG mice, MISTRG mice support robust en-
graftment of this AML subtype. The same study identified
M-CSF as a critical factor for AML engraftment, a finding
that could potentially be exploited therapeutically. In an-
other study, favourable risk AML and acute promyelocytic
leukaemia were successfully transplanted into engineered
human bone fragments, so called ossicles, implanted into
immune-deficient mice [48].
Only a few studies have successfully demonstrated en-
graftment of less aggressive diseases such as myelodys-
plastic syndromes and myeloproliferative neoplasms in
immune-compromised mice. Engraftment of certain hu-
man myelodysplastic syndrome subtypes was improved
by transplantation into newborn animals and by direct in-
trafemoral transplantation into adults [49, 50]. Other ap-
proaches include the co-transplantation of myelodysplastic
syndrome samples along with healthy mesenchymal stro-
mal cells and transplantation into ossicles (see above) [48,
51]. Similar approaches have also been undertaken for the
development of myeloproliferative neoplasm PDX models.
In conclusion, PDX models for myeloid neoplasms have
significantly contributed to understanding the pathogenesis
of AML in recent decades and today have become a stan-
dard in preclinical testing of novel therapeutic regimens.
Future studies will show whether the knowledge gained
from these models can be directly translated into clinical
practice and help elucidate the pathogenesis of less aggres-
sive diseases.
Lymphoid neoplasms
Lymphoid neoplasms include acute and chronic leukaemia
as well as a wide range of lymphomas that are charac-
terised by variable stages of B and T cell maturation [52].
Acute B-precursor lymphoblastic leukaemia is a malignant
disease most commonly found in children; in adulthood
chronic lymphoblastic leukaemia (CLL) is more common
[53]. The first leukaemia xenograft model was established
more than two decades ago with AML patient samples, and
provided the first functional insights into the haematopoi-
etic hierarchy of this disease [38]. Systematic studies for
acute lymphoblastic leukaemia (ALL) later set the stage
for comprehensive preclinical testing [54, 55].
The development of NSG mice (see introduction) substan-
tially improved the engraftment capacities of human lym-
phoma, B and T cell leukaemia [56–58]. In contrast to
AML, emerging evidence indicates that most ALL cells
can propagate the disease in this xenotransplantation mod-
el [59–61]. Between 50 and 100 cells are sufficient to
reconstitute the leukaemic phenotype observed in the di-
agnostic sample [60–63]. In fact, leukaemia can be recon-
stituted from bone marrow samples with minimal residual
disease [64] (fig. 4).
These models also contributed to the understanding of
leukaemic stem cell plasticity found in certain ALL sub-
types, in particular mixed lineage leukaemia (MLL)-re-
arranged leukaemia [65]. They further clarified the role
of the MLL-rearranged ALL lineage switch to escape im-
munotherapeutic approaches that target CD19 on ALL
cells [66]. Residual subclones that retained CD19 expres-
sion and displayed a myeloid phenotype in patients could
reconstitute both a myeloid and lymphoid leukaemia in
xenografts. Thus, this model can be used to address essen-
tial functional questions with leukaemia cells that are di-
rectly derived from patients. In fact, several publications
have shown that leukaemia xenografts can recapitulate the
clonal complexity of ALL with reasonable fidelity [60, 63,
64, 67, 68].
Recent studies indicate that this approach is also effective
for adult leukaemia samples, although conditioning using
total body irradiation of NSG may improve the engraft-
ment capacities [69]. Lymphomas represent one of the
most complex and heterogeneous set of malignancies and
although a high diversity of PDX models are available,
they fall short in truly representing patient heterogeneity
[70, 71]. Additionally, the injection of lymphoma cells into
specific tissues might introduce potential bias. However,
tumour injection models are useful for studying the impact
of different mutations and drugs on tumour aggressiveness
[72–74]. Furthermore, repositories of AML, ALL and lym-
phoma PDXs will be available that should facilitate trans-
lational research forward [42].
The use of xenograft ALL models for preclinical testing of
predictive biomarkers and drug efficacies offers new pos-
sibilities for translational research and is a big step towards
clinical trials [64, 68, 75–77]. Finally, given the high de-
gree of phenotypic and genotypic conservation between
patient samples and their corresponding xenografts, this
model will enable us to study the interaction of leukaemic
cells within their complex niche in the bone marrow, which
may provide improved and more precise rationales for
therapeutic targeting of resistant leukaemia clones in their
microenvironment [61, 78] (fig. 4). Xenograft models for
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chronic lymphoid malignancies are also being developed
using “next-generation” humanised mouse strains and will
be extremely useful for preclinical testing of novel thera-
pies [79].
Immune system and infectious diseases
Human innate and adaptive immune responses in hu-
manised mice
The human leucocytes of mice with human immune sys-
tem components reconstituted from transferred human
haematopoietic progenitor cells (HIS mice) show similari-
ties to cord blood immune cells. Most B cells have a tran-
sitional or naïve phenotype, NK cells have a low frequency
of killer immunoglobulin-like receptor (KIR) expression
and still contain a CD56 negative subpopulation, and most
T cells are naïve [80–83]. In addition, lymph nodes and
mucosal secondary lymphoid tissues are poorly developed
as a result of blocked lymphoid tissue inducer (LTi) cell
differentiation in the absence of the cytokine receptor com-
mon gamma chain (γc) in most mouse strains that sup-
port efficient human immune compartment reconstitution
[84]. Accordingly, cell-mediated immune responses can be
mounted, while humoral immune responses are compro-
mised, in HIS mice. Dendritic cells (DCs), the antigen-
presenting cells that coordinate both cell-mediated and hu-
moral immune responses, are reconstituted at frequencies
and with a subset representation similar to that of human
secondary lymphoid tissues [85–87]. Furthermore, they re-
act to adjuvant exposure in the form of defined toll-like
receptor (TLR) ligands similar to human peripheral blood
DCs, whereas mouse DCs within HIS mice react with a
different hierarchy that is consistent with the dissimilar
TLR distribution between mouse and man [85]. Antigen
that is targeted to these human DCs with suitable adjuvants
can elicit CD4+ T cell responses [85, 88]. These are HLA
restricted and can recognise a diverse set of antigen-de-
rived epitopes. In addition, primed CD4+ and CD8+ T cell
clones can target EBV-transformed B cells and, in HLA
transgenic HIS mice, specificities develop which are also
found in human EBV carriers [80, 89–91]. These T cell re-
sponses restrict viral loads not only during EBV infection,
but also after human immunodeficiency virus (HIV) and
hepatic adenovirus infection of HIS mice [80, 89, 92–94].
Therefore, protective human T cell responses can be repro-
duced in the humanised mouse model.
In addition to priming T cells, DCs are also capable to acti-
vate innate lymphocytes. Indeed, human DC-activating ad-
juvants render NK cells of HIS mice more cytotoxic [81].
The early differentiated NK cell compartment of HIS mice
can restrict lytic EBV infection [95] and recognises tumour
cells with their distinct set of human NK cell-specific re-
ceptors [81, 96]. Furthermore, reconstituting two human
immune systems in parallel from two donors that are mis-
matched in the HLA ligands of inhibitory NK cell recep-
tors changes the education of these innate cytotoxic lym-
Figure 4: Generation of PDX models for preclinical studies. Patient-derived xenograft models of B-acute lymphocytic leukaemia (ALL), T-
ALL and lymphoma can be generated from different disease time points like diagnosis, remission or relapse. PDX stability and complexity are
highly conserved and can be proven by targeted sequencing, FISH (fluorescence in situ hybridisation) or FACS (fluorescence activated cell
sort) analysis. PDX models can be used for a broad range of translation studies. Use of a co-culture system with mesenchymal stem cellss en-
ables in vitro approaches for drug efficacy testing or biomarker identification. The high conservation of patient samples and xenografts enables
the development of in vivo models for pharmacological screens, cell manipulations with CRISPR or the study of niche interactions in the mi-
croenvironment of the cancer cells.
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phocytes and allows the resulting NK cell population to
more efficiently control EBV infection in the mixed B cell
compartment [83]. This improved innate immune control
most likely results from efficient targeting of EBV-infected
B cells of one donor by the less inhibited NK cell compart-
ment of the other donor. Thus, NK cell responses that are
similar to those in small children can be modelled in HIS
mice and manipulated for improved EBV-specific immune
control.
In contrast to functional DC, T and NK cell responses, hu-
moral immune responses are difficult to achieve. Usual-
ly only a minority of HIS mice develop specific isotype-
switched antibody responses after viral infection [97]. Fur-
thermore, the steady-state levels of human IgG in HIS mice
are with below one microgram per millilitre more than a
thousand-fold lower than in human serum [9, 82]. Accord-
ingly, germinal centres are rarely observed, but even so the
B and T cell zone is segregated in secondary lymphoid tis-
sues of HIS mice (fig. 5) [85]. However, most B cells are
of transitional and naïve phenotype, and follicular helper
T cells that assist B cells in the germinal centre reaction
are absent [82]. Interestingly, providing additional DCs ei-
ther by adoptive transfer or possibly also by expansion of
the reconstituted human DC populations might at least par-
tially overcome these deficiencies and lead to B cell plas-
mablast differentiation, follicular helper T cell priming and
antigen specific IgG responses [82]. Therefore, humoral
immune responses are largely absent in HIS mice, but fur-
ther manipulation of this model system might allow them
to develop.
In addition to the compromised B cell compartment, it re-
mains unclear if there is sufficient human myeloid recon-
stitution in HIS mice. Although DCs are found at con-
siderable frequencies, it has been argued that macrophage
populations are poorly developed [98]. Along these lines,
human alveolar macrophages were able to protect HIS
mice from lung proteinosis only when they developed in
a human IL-3 and GM-CSF transgenic mouse background
[98]. However, some lung infections could be studied in
the absence of this enhanced human myeloid cell reconsti-
tution in HIS mice. Influenza A virus infection caused the
induction of virus-specific T cell responses and Mycobac-
terium tuberculosis infection led to granuloma formation
[99, 100]. Therefore, whether enhanced myeloid cell re-
constitution is beneficial or not might depend on the par-
ticular application of HIS mice. With respect to immune
responses, it has to be kept in mind that the immunoregu-
latory function of some myeloid cells might be detrimen-
tal for the induction of immune responses. It has been
shown that stem cell factor, IL-3 and GM-CSF transgenic
mice allow elevated myeloid cell reconstitution, although
at the same time expanded FoxP3 positive regulatory T
cells could dampen the induction of immune responses
[101]. Thus, HIS mice reconstitute a wide variety of hu-
man immune system compartments. Some of these already
demonstrate functionality in the currently available mod-
els, whereas others, especially B cells, might benefit from
additional manipulations of the model system in order to
obtain the ability to execute their full range of immune
functions. The resulting novel HIS mice may allow for a
Figure 5: Human immune compartments of HIS mice. HIS mice reconstitute most human immune compartments within 3 months after
neonatal intrahepatic human CD34+ haematopoietic progenitor cell transfer. In the spleen of NSG mice, macrophages (CD68), dendritic cells
(CD205), T cells (CD3) and B cells (CD20) can be found in the white pulp.
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more comprehensive investigation of human immune re-
sponses.
Espstein-Barr virus research with humanised mice
The ubiquitous gamma-herpes virus, Espstein-Barr virus
(EBV), is the cause of infectious mononucleosis, and is as-
sociated with lymphomas predominantly of B cell origin
and certain epithelial cell malignancies. Owing to its ex-
clusive tropism for humans, studying this virus in vivo is
difficult and was until recently restricted to related viruses
in old-world monkeys [102]. However, EBV was not on-
ly the first human oncogenic virus to be discovered, fifty
years ago [103], but it was also the first pathogenic agent
to be studied in HIS mice [9]. EBV infection of B cells
in HIS mice can result in asymptomatic infection or lym-
phoproliferative disease, depending on the infectious dose
[80, 104]. Both latent and lytic EBV infection can be mod-
elled in HIS mice (fig. 6). Depending on the viral strain,
the majority of infected B cells either express all eight la-
tent EBV proteins and only a minority initiates lytic repli-
cation (latency III predominates after B95-8 infection), or
the frequency of lytically EBV replicating cells can be sig-
nificantly increased (high lytic replication after M81 infec-
tion) [105]. The Hodgkin’s and Burkitt’s lymphoma-asso-
ciated latencies I and II have been suggested to be present
after HIS mouse infection with EBV [106–108], but they
probably contribute to infection only at very low frequen-
cies.
Apart from these virological parameters, some hallmarks
of EBV specific immune control can also be recapitulated
in HIS mice (fig. 6). The importance of NK cells in pro-
tecting from EBV-associated diseases, especially in the in-
nate restriction of primary infection, was first demonstrat-
ed in HIS mice. Depletion of NK cells prior to infection
revealed a protective effect against lytic EBV replication
[83, 95]. The importance of NK cells in recognising lytic
replication during acute EBV infection was then also con-
firmed in longitudinal studies of paediatric patients with
infectious mononucleosis [109], indicating the predictive
nature of the humanised mouse model for EBV-associated
diseases.
After the transient and protective NK cell proliferation,
CD8+ T cells massively expand during EBV infection of
HIS mice [80, 89]. Both CD4+ and CD8+ T cells control
viral loads, whereas CD8+ T cells are more important in
preventing EBV-associated lymphomas [80]. Among these
expanding CD8+ T cells, both latent and lytic EBV antigen
specificities can be detected in HLA transgenic HIS mice
[80, 90, 91]. Furthermore, a protective effect of EBV-spe-
cific T cell clones, which target lytic antigens against high
viremia and extra-lymphoid lymphoma genesis, could be
documented [91], suggesting the importance of these
specificities for future vaccine development against EBV.
Indeed, targeting of EBV antigens to DC populations is un-
der investigation in HIS mice [85, 110]. However, these
distinct antigen specificities are so far still difficult to mod-
ulate and the role of their effector functions cannot be as-
sessed. The generation of recombinant viral vectors to ma-
nipulate the expression of certain genes in the developing
haematopoietic lineage would constitute a valuable tool
for assessing the importance of specific human immune
functions during EBV-associated lymphoma genesis. For
the investigation of adaptive cellular immune responses to
EBV, T cell receptor transgenes would allow the develop-
ment of T cell populations that could not only be tracked
during the course of EBV challenge, but also further in-
vestigated for their protective potential during viral infec-
tion. Together with recombinant manipulation of the EBV
Figure 6: HIS mice can be persistently infected with Epstein-Barr virus (EBV) and develop immune responses to the infection. Mice
that have been reconstituted by means of neonatal intrahepatic injection with human CD34+ haematopoietic progenitor cells develop viraemia
upon intraperitoneal EBV infection. Lytic replication deficient virus (BZLF1-) has a lower viral titre at 3 weeks after infection. NK cells expand to
lytic EBV infection at 4 weeks after infection and CD8+ T cells react to both lytic and latent infection with expansion by 5 weeks of infection.
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genome [91, 95, 107, 111], the aforementioned strategies
might lead to predictive preclinical models for relevant
human diseases, which would provide insight that can be
more readily translated into targeted clinical research.
Human immunodeficiency virus infection in human-
ised mice
The human immunodeficiency virus (HIV) type-1 belongs
to the lentivirus genus (family of retroviruses), comprising
five serogroups that can infect a number of vertebrates.
Clinical hallmarks of lentiviral infections are chronicity,
intra-host evolution and cellular tropism [112]. Their basic
genomic structure comprises the long-terminal repeat
(LTR; transcription start), three genes encoding the struc-
tural proteins – gag, pol and env – and regulatory genes
(Tat and Rev) [113]. Notably, accessory genes contribute
to their virulence [114, 115].
HIV is a human-specific virus; the HIV pandemic counts
currently 36.7 million of HIV-infected human
(http://www.who.int/hiv/en/). HIV infects mainly CD4+ T-
cells and macrophages, leading to their progressive de-
pletion [116, 117] and exhaustion [118, 119]. Moreover,
HIV can remain latent by integrating its genome into the
host chromosome, allowing viral rebound upon interrup-
tion of antiretroviral treatment (ART). Many in vivo as-
pects of HIV infection remain an enigma, e.g., HIV trans-
mission [120], HIV latency [121, 122], tissue target cells
[123–125], role of the HIV accessory genes [126], immune
activation [127] and co-infection pathogenesis [128–130].
Of course, a key in any research efforts is the identification
of novel therapeutic approaches [131–136].
The lack of a small HIV animal model has hampered HIV
research since its discovery. The feline immunodeficiency
virus (FIV), the simian immunodeficiency virus (SIV) and
hybrid viruses between SIV and HIV (SHIV) have been
used as a substitute for HIV in domestic cats or nonhuman
primates, respectively. Findings with these models must
further be validated with HIV itself. Notably, the “first”
generation of hu mice, already used in the 1980s i.e., the
SCID hu thy/liv or hu PBL SCID [137–142], lacked de no-
vo multilineage haematopoiesis and/or suffered from graft-
versus-host disease (GvHD), limiting their use in HIV re-
search.
The “new” generation of hu mice (see introduction) are
highly sensitive to HIV infection (figs 7 and 8) [97,
143–146] and recapitulate key features of HIV infection in
human, e.g., dissemination [146], pathogenesis [147] and
latency [148]. In the following, we will give a short update
about the various humanized mouse models currently used
in HIV research, including the pros and cons (figs 7 and 8).
NSG mice intraperitoneally transplanted with adult human
peripheral blood mononuclear cells s comprise a simple
and direct lymphoid-based model that allows HIV infec-
tion over 10 weeks [149]. This model is similar to the hu
PBL SCID mouse model [4] and has similar limitations,
i.e., lack of multilineage haematopoiesis and risk of
GvHD. Thus, we would like to highlight only one study,
which showed the value of this model to assess the pres-
ence of residual HIV reservoir in immunosuppressed pa-
tients, employed as a murine viral outgrowth assay [150].
Hu mice based on the transplantation of human CD34+
HSPCs develop long-term de novo multilineage
haematopoiesis and immunity [9] with low prevalence of
GvHD. They are very valuable for long-term studies,
studying HIV infection in deep tissues, HIV latency estab-
lishment [146, 148] and virus-specific CD8+ T-cell devel-
opment [92].
These mice have been very useful for dissecting the path-
ogenic role of the HIV accessory proteins and for studying
HIV-associated immune activation. For example, by use of
these mice, the destructive potential of a distinct motif of
the Nef gene, the secretory modification region (SMR) by
promoting CD4 apoptosis and a cytokine storm was con-
vincingly demonstrated [151]. As related to HIV-associ-
ated immune activation, a recent study reported how ex-
osomes containing transactivation response (TAR) RNA-
stimulated macrophages and plasmacytoid dendritic cells
(pDC), thereby promoting interferon-beta (IFN-β) and
IL-6 secretion [152].
Notably, NSG mice have been successfully used to investi-
gate novel treatment approaches (fig. 7), pre-exposure pro-
phylaxis (PreP) against vaginal transmission [153, 154],
testing novel innovative compounds [155], optimised long-
acting ART [156–158] or broadly neutralising antibodies
(bNAb) [159]. Importantly, bNAb also reduced the latent
reservoir size, either through FcүR engagement [160] or by
additional treatment with latency reversing agents [161] –
the latter was the first study that successfully targeted the
latent reservoir for its eradication and thus a potential cure
of HIV. Similarly, gene therapy-based approaches resulted
in functional cure in NSG mice.
Bone marrow, liver, thymus mice (BLT) produced by con-
comitant transplantation of fetal liver/thymus tissues with
CD34+ cells into adult immunodeficient mice are a widely
Figure 7: Humanised mice are highly susceptible to human immunodeficiency virus (HIV) and allow the examination investigational
drugs. Humanised mice were infected with the CCR5-tropic HIV strain, YU-2, and viral load was monitored over time with quantitative real-
time PCR. The left panel shows untreated mice. The middle panel shows mice treated with antiretroviral therapy (tenofovir, lamivudine and ral-
tegravir). The right panel shows mice treated with an investigational compound. The grey shaded area indicates the treatment period. The
filled and empty circles in the untreated group represent mice from two independent cohorts.
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Figure 8: Human cells expressing p24 (dark red) in the lymph node of an HIV-infected NSG mouse. The amplified image at the top left
corner shows multi-nucleated giant cells, i.e., infected T cells that fuse with each other inducing syncytia. The lower left image shows a single
HIV-infected macrophage. The lower right image depicts HIV-infected T cells among other HIV-infected cells.
used model. The thymic tissue resulted in an increase of
T cell reconstitution, maturation and selection, enabling
the generation of an MHC-restricted adaptive immune re-
sponse from which HIV shows immune escape [162–164].
Notably, engraftment of human cells in the gastrointestinal
tract and female reproductive tract is very prominent as
compared with NSG mice, which permits study of HIV
transmission and replication in mucosal tissues [165–169].
Viral replication was found preferentially in intestinal
crypts, which released a pool of both immature and mature
virions [170]. These findings were in contradiction to in
vitro findings, where virion maturation occurred quickly,
emphasising the value of in vivo investigations with the
corresponding microenvironment [171].
Furthermore, BLT mice facilitated broad HIV transmission
research; for example, ART reduced the amount of cell-
free virus in the female reproductive tract and in the breast
milk, overall decreasing the prevalence of HIV transmis-
sion [172, 173]. Another study showed that early ART
initiation was able to preserve the immune system and
functionally control productive HIV infection thanks to
the development of a HIV-specific immune response [174,
175]. These results corroborated findings from the Visconti
study in humans, where 14 patients treated during primary
infection were able to constrain HIV infection for several
years without treatment [174, 175].
Moreover, numerous prophylactic approaches have been
validated using this model. For instance, lentiviral modifi-
cation of HSPCs with a polymeric anti-HIV IgA construct
or on adeno-associated virus (AAV) containing a bNAb
(VRC07) hampered mucosal HIV transmission [176, 177].
Last, but not least, a study examining cross-species trans-
mission events from chimpanzees to humans: Yuan et al.
decoded critical viral envelop mutations required to allow
HIV zoonosis [178]. Altogether, the BLT model is highly
valuable, especially for mucosal tissues and adaptive im-
mune response analysis.
More and more sophisticated humanised mice models are
generated in order to recapitulate the human cell distrib-
ution and functionality in animals and which are exam-
ined for studying HIV. For example, MITRG and MISTRG
mice demonstrated superior myeloid and NK cell devel-
opment and function, in comparison to preceding models
[17]. Deng et al., using MISKITRG mice demonstrated the
potential of cytotoxic CD8+ T cells (CTL) obtained from
chronically infected patients, to constrain HIV released
from reactivated latent cells [179].
To address more precise questions, highly specific human-
ised mouse models are used, such as, the T cell only and
macrophage only mouse model (TOM and MOM, respec-
tively) that permits development of only a specific human
lineage. TOM can be readily infected with HIV and estab-
lishment of latency occurred in absence of other cell types
[180]. Similarly, MOM confirmed the capacity of some
strains of HIV to replicate and infect macrophages in vivo
[181].
The studies mentioned above represent only a small frac-
tion of insights gained in HIV infection/pathogenesis and
cure using humanised mice that underscores their value for
studying HIV. They likely represent the long awaited small
animal model for the HIV research community. Since vari-
ous models are available, and more will be available soon,
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the HIV researcher will be faced with the challenge to
identify the most suitable model to address their research
question.
Conclusions and outlook
Our understanding of human haematopoiesis and immu-
nity has extensively evolved with the help of humanised
mouse models. Currently, there are an increasing number
of models for more aggressive neoplasms, such as AML
and ALL, and for infectious diseases, such as EBV and
HIV. Experimental strategies used in order to improve
these and create new models include the expression of sup-
portive human factors by genetic modification of mice, the
co-transplantation of human mesenchymal stem cells, and
the xenotransplantation of humanised ossicles. One partic-
ularly interesting approach is the use of the CRISPR/Cas9
technology for fast genetic modification of humanised host
strains to express specific human factors. Despite on-going
efforts, modelling less aggressive neoplasms, reproducing
disease heterogeneity seen in patients, and probing certain
immune cell pathologies is still a challenge that researchers
face. Future models will need to support engraftment of
the majority of patient samples for any given neoplasm or
infection to allow researchers to draw substantial conclu-
sions and predict accurate therapy responses in humans.
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